Having trouble accessing articles? Reset your cache.

AN2728: Phase II data

The double-blind, dose-ranging, U.S. and Australian Phase II AN2728-AD-204 trial in 86 patients aged 12-17 years with mild to moderate atopic dermatitis showed that twice-daily topical 2% AN2728 for 28 days improved ADSI scores from baseline to day 29,

Read the full 395 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers